European Dermatology Forum recommends Leo Pharma drug in line with other biologics
The guiding dermatological organization has put Leo Pharma’s eczema drug, Adtralza, in the same class as other biologics. Recently, England and Wales differed in opinion when recommending it as a second-line treatment.
by christian bundgaard, translated by daniel pedersen
Over the summer, Leo Pharma can celebrate something of a milestone for its newest drug, Adtralza.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma eczema treatment recommended in two UK countries
For subscribers
Analyst predicts slow start for Leo Pharma's Adtralza in UK
For subscribers
.jpg)
.jpg&w=384&q=75)
